I've come to the same conclusion as MarsC. As for being cashflow positive, ACR have had ample time to inform shareholders how our testosterone generic is going. Dash Pharma would know how it's going after some 8-9 months, and if it wasn't working out for them they certainly would have told ACR by now. So whilst not expecting much, any good news will surprise. It's some 7-8 years since this path was taken and we are getting close to the Day of Truth.
- Forums
- ASX - By Stock
- ACR
- Ann: Acrux's fifth generic dossier accepted by FDA for review
Ann: Acrux's fifth generic dossier accepted by FDA for review, page-23
Featured News
Add ACR (ASX) to my watchlist
|
|||||
Last
6.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $17.44M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 32722 | 6.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
6.4¢ | 50000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 32722 | 0.061 |
2 | 116666 | 0.060 |
2 | 28810 | 0.058 |
2 | 167543 | 0.057 |
2 | 67857 | 0.056 |
Price($) | Vol. | No. |
---|---|---|
0.064 | 50000 | 1 |
0.065 | 73455 | 1 |
0.070 | 50000 | 1 |
0.072 | 47301 | 1 |
0.073 | 30000 | 3 |
Last trade - 11.45am 11/07/2024 (20 minute delay) ? |
Featured News
ACR (ASX) Chart |
Day chart unavailable